Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: German Center for Lung Research, Chungbuk National University, Chungbuk National University Hospital, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité – Universitätsmedizin Berlin, Russian Cancer Research Center NN Blokhin, The Maria Sklodowska-Curie National Research Institute of Oncology, Institute of Oncology NN Petrov, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Port Macquarie Base Hospital, Hôpital privé Clairval, Merck & Co., Inc., Rahway, NJ, USA (United States), MSD (UK) Limited (United Kingdom), Rutgers, The State University of New Jersey, Rutgers Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4400108842